RT Journal Article
SR Electronic
T1 Oral, similar to intranasal, administration of oxytocin decreases top-down social attention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.20.21263870
DO 10.1101/2021.09.20.21263870
A1 Zhuang, Qian
A1 Zheng, Xiaoxiao
A1 Yao, Shuxia
A1 Zhao, Weihua
A1 Becker, Benjamin
A1 Xu, Xiaolei
A1 Kendrick, Keith M.
YR 2022
UL http://medrxiv.org/content/early/2022/04/15/2021.09.20.21263870.abstract
AB The neuropeptide oxytocin (OXT) modulates social cognition by increasing attention towards social cues and may have therapeutic potential for impaired social attention in disorders such as autism. Intranasal administration of OXT is widely used to examine its functional effects in both adults and children and is assumed to enter the brain directly via this route. However, OXT can also influence brain function via increased blood concentrations and we have recently shown that orally (lingual) administered OXT also modulates neural responses to emotional faces and may be better tolerated for therapeutic use. Here, we examined if 24IU OXT administered orally can facilitate social attention. In a randomized, placebo-controlled, pharmacological study we used a validated emotional anti-saccade eye-tracking paradigm to explore effects of oral OXT on bottom-up and top-down attention processing in 80 healthy male subjects. Our findings showed in terms of top-down attention, oral OXT increased errors for both social (angry, fearful, happy, sad and neutral emotion faces) and non-social stimuli (oval shapes) in the anti-saccade condition but only increased response latencies in the social condition. It also significantly reduced post-task state anxiety but this was not correlated with task performance. Comparison with our previous intranasal OXT study using the same task revealed both routes have a similar effect on increasing anti-saccade errors and response latencies and reducing state anxiety. Overall, findings suggest that oral administration of OXT produces similar effects on top-down social attention control and anxiety as intranasal administration and may therefore have therapeutic utility.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov ID:NCT04493515;NCT04815395Funding StatementThis work was supported by the National Natural Science Foundation of China (grant numbers 31530032,KMK and 91632117,BB), Key Technological Projects of Guangdong Province (grant number 2018B030335001,KMK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the local ethics committee of University of Electronic Science and Technology of China (UESTC).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in the manuscript could be accessible from authors on the request